Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib, Chemotherapy, and Transplantation for Ph+ ALL
NCT00039377Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2002
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by National Cancer Institute. Primary endpoint: Disease Free Survival at 10 years. Started Apr 2002; status: completed.
02
Drugs
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00039377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039377.